Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices.  Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 29, 12, 1, 76, 42 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 8 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Cystic Fibrosis – Overview
Cystic Fibrosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cystic Fibrosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cystic Fibrosis – Companies Involved in Therapeutics Development
4D Molecular Therapeutics Inc
AbbVie Inc
Abeona Therapeutics Inc
Aceragen Inc
Aeon Respire Inc
Agile Sciences Inc
AiCuris Anti-infective Cures AG
Airbase Breathing Co LLC
Airway Therapeutics Inc
AlgiPharma AS
Antabio SAS
Arch Biopartners Inc
Arcturus Therapeutics Holdings Inc
Armata Pharmaceuticals Inc
Arrevus Inc
Arrowhead Pharmaceuticals Inc
Astria Therapeutics Inc
Atlantic Healthcare Plc
Avidin Biotechnology Ltd
Biofilm Pharma
Biolytx Pharmaceuticals Corp
BiomX Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Branca Bunus Ltd
Breathe Easy Therapeutics Ltd
BridgeBio Pharma Inc
Calista Therapeutics Inc
Calithera Biosciences Inc
Carbon Biosciences Inc
Chiesi Farmaceutici SpA
Cilian AG
Clarametyx Biosciences Inc
ContraFect Corp
Copernicus Therapeutics Inc
CRISPR Therapeutics AG
CSA Biotechnologies LLC
Cyclacel Pharmaceuticals Inc
Cyclenium Pharma Inc
Destiny Pharma Plc
DiscoveryBiomed Inc
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
EmphyCorp Inc
enGene Inc
Enterprise Therapeutics Ltd
Entrinsic Bioscience Inc
Evaxion Biotech ApS
Evotec SE
F. Hoffmann-La Roche Ltd
Feldan Therapeutics Inc
Felix Biotechnology Inc
Helperby Therapeutics Group Ltd
Hunterian Medicine LLC
Icagen Inc
Insmed Inc
Invion Ltd
Kamada Pharmaceuticals
Kither Biotech Srl
Krystal Biotech Inc
Lakewood-Amedex Inc
Lamellar Biomedical Ltd
Laurent Pharmaceuticals Inc
Loxegen Pty Ltd
MannKind Corp
Mariposa Health Ltd
Microbion Corp
Mucokinetica Ltd
Nabriva Therapeutics Plc
Nanogenics Ltd
Neupharma Srl
New Amsterdam Sciences Inc
Novabiotics Ltd
Omnispirant Ltd
Orphomed Inc
OrPro Therapeutics Inc
Oryn Therapeutics
Parion Sciences Inc
Peptilogics Inc
Peter Biotherapeutics Inc
Pharmaero ApS
PhaseBio Pharmaceuticals Inc
Progenra Inc
Prolong Pharmaceuticals LLC
PureIMS BV
Pylum Biosciences Inc
RAGE Biotech Pty Ltd
Rare Partners Srl
Reata Pharmaceuticals Inc
Recode Therapeutics Inc
Renovion Inc
Respirion Pharmaceuticals Pty Ltd
Riptide Bioscience Inc
RS BioTherapeutics Inc
Saliogen Therapeutics Inc
San Rocco Therapeutics LLC
Sanofi
Santhera Pharmaceuticals Holding AG
Sarcomed AB
SciBac Inc
SciClone Pharmaceuticals Holdings Ltd
Shape Therapeutics Inc
Silurian Pharmaceuticals Inc
Sionna Therapeutics Inc
SOLA Biosciences LLC
SolAeroMed Inc
Specific Biologics Inc
Spexis AG
Spirovant Sciences Inc
SpliSense Ltd
Synedgen Inc
Synovo GmbH
Synspira Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tavanta Therapeutics Inc
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Thirty Respiratory Ltd
Translate Bio Inc
Vast Therapeutics Inc
Vectura Group Plc
Vera Therapeutics Inc
Verona Pharma Plc
Vertex Pharmaceuticals Inc
VGSK Technologies Inc
Vironika LLC
Yumanity Therapeutics Inc
Zambon Co SpA
Zata Pharmaceuticals Inc
Cystic Fibrosis – Drug Profiles
(ammonium chloride + citric acid + sodium citrate) – Drug Profile
(elexacaftor + ivacaftor + tezacaftor) + ivacaftor – Drug Profile
(ethylenediaminetetraacetic acid + sodium nitrite) – Drug Profile
(ivacaftor + lumacaftor) – Drug Profile
(ivacaftor + tezacaftor + bamocaftor potassium) – Drug Profile
(ivacaftor + tezacaftor) + ivacaftor – Drug Profile
4D-710 – Drug Profile
ABBV-191 – Drug Profile
ABO-401 – Drug Profile
ACF-516 – Drug Profile
ADDITIONAL SMALL MOLECULES 1 – Drug Profile
AGL-503 – Drug Profile
alidornase alfa – Drug Profile
alpha-1 proteinase inhibitor (human) second generation – Drug Profile
ANT-3273 – Drug Profile
APPA-02 – Drug Profile
ARCT-032 – Drug Profile
ARO-ENaC2 – Drug Profile
ARV-1907 – Drug Profile
ascorbic acid – Drug Profile
AT-010 – Drug Profile
AvR-2V10 – Drug Profile
BBP-321 – Drug Profile
BFP-002 – Drug Profile
BFP-102 – Drug Profile
BI-1323495 – Drug Profile
BI-3720931 – Drug Profile
BIOC-51 – Drug Profile
BOS-857 – Drug Profile
BP-002 – Drug Profile
BrB-102 – Drug Profile
brensocatib – Drug Profile
brevenal – Drug Profile
BX-004 – Drug Profile
Calcaftor – Drug Profile
CAT-5571 – Drug Profile
CB-280 – Drug Profile
CF-370 – Drug Profile
CGT-001 – Drug Profile
CHF-6333 – Drug Profile
CMTX-101 – Drug Profile
colistimethate sodium – Drug Profile
CSA-13 – Drug Profile
cysteamine – Drug Profile
Cystic Fibrosis – Drug Profile
dirocaftor – Drug Profile
dornase alfa – Drug Profile
Drug for Cystic Fibrosis – Drug Profile
Drug to Inhibit SLPI for Asthma and Cystic Fibrosis – Drug Profile
Drugs for Cystic Fibrosis – Drug Profile
Drugs to Activate CFTR for Cystic Fibrosis – Drug Profile
EBX-001 – Drug Profile
ECP-104 – Drug Profile
EG-i08 – Drug Profile
ELX-02 – Drug Profile
ensifentrine – Drug Profile
ETD-001 – Drug Profile
ETD-002 – Drug Profile
ETX-001 – Drug Profile
EVXB-2 – Drug Profile
fenretinide – Drug Profile
FTX-003 – Drug Profile
fusidic acid – Drug Profile
galicaftor – Drug Profile
Gene Therapy for Cystic Fibrosis – Drug Profile
Gene Therapy for Cystic Fibrosis and Retinitis Pigmentosa – Drug Profile
Gene Therapy to Activate CFTR for Cystic Fibrosis – Drug Profile
heparin sodium – Drug Profile
HY-006 – Drug Profile
ICL4 Additional Candidates – Drug Profile
ivacaftor – Drug Profile
KB-407 – Drug Profile
KIT-2014 – Drug Profile
lefamulin acetate – Drug Profile
LMS-611 – Drug Profile
lonodelestat – Drug Profile
MG-277 – Drug Profile
MRT-5005 – Drug Profile
Mul-1867 – Drug Profile
murepavadin – Drug Profile
N-115 – Drug Profile
nadolol – Drug Profile
nafamostat mesylate – Drug Profile
NAS-415 – Drug Profile
navocaftor – Drug Profile
NBD1 Additional Candidates – Drug Profile
nesolicaftor – Drug Profile
niclosamide – Drug Profile
NU-8 – Drug Profile
OligoG – Drug Profile
Oligonucleotide to Activate CFTR for Cystic Fibrosis – Drug Profile
Oligonucleotides for Cystic Fibrosis – Drug Profile
Oligonucleotides to Activate CFTR for Cystic Fibrosis – Drug Profile
Optate – Drug Profile
ORP-100S – Drug Profile
ORP-110 – Drug Profile
OTP-602 – Drug Profile
P-2114 – Drug Profile
P-2176 – Drug Profile
Pemziviptadil – Drug Profile
PLG-0301 – Drug Profile
posenacaftor – Drug Profile
pravibismane – Drug Profile
Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis, Hospital Acquired Pneumonia and Diabetic Foot Infection – Drug Profile
PTINC-733 – Drug Profile
RBR-042 – Drug Profile
Recombinant Enzyme to Inhibit DNA for Cystic Fibrosis – Drug Profile
renzapride – Drug Profile
RP-557 – Drug Profile
RSBT-001 – Drug Profile
RTX-0001 – Drug Profile
RVT-801 – Drug Profile
S-1226 – Drug Profile
S-1229 – Drug Profile
Sanguinate – Drug Profile
SBI-001 – Drug Profile
SCB-203 – Drug Profile
seliciclib – Drug Profile
SHP-111 – Drug Profile
SHP-636 – Drug Profile
SION-109 – Drug Profile
SION-638 – Drug Profile
Small Molecule for Cystic Fibrosis – Drug Profile
Small Molecule to Activate CFTR for Cystic Fibrosis – Drug Profile
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease – Drug Profile
Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD – Drug Profile
Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis – Drug Profile
Small Molecules for Cystic Fibrosis – Drug Profile
Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis – Drug Profile
Small Molecules for Respiratory Diseases – Drug Profile
Small Molecules to Activate CFTR for Cystic Fibrosis – Drug Profile
Small Molecules to Block SCNN1 for Cystic Fibrosis – Drug Profile
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis – Drug Profile
Small Molecules to Inhibit Penicillin Binding Protein for Gram-Negative Bacterial Infections and Cystic Fibrosis – Drug Profile
SNSP-113 – Drug Profile
sodium calcium edetate + tobramycin – Drug Profile
sodium nitrite – Drug Profile
SOL-512 – Drug Profile
SPIRO-2101 – Drug Profile
SPIRO-2102 – Drug Profile
SPIRO-2110 – Drug Profile
SPL-16 – Drug Profile
SPL-232 – Drug Profile
SPL-24N – Drug Profile
SPL-5A – Drug Profile
SPL-5B – Drug Profile
SPL-8423 – Drug Profile
SRI-41315 – Drug Profile
SYD-0073 – Drug Profile
SYGN-303 – Drug Profile
TA-270 – Drug Profile
TAVT-135 – Drug Profile
teicoplanin – Drug Profile
thymalfasin – Drug Profile
TMD1 Candidates – Drug Profile
tobramycin – Drug Profile
tobramycin + triclosan – Drug Profile
trimethylangelicin – Drug Profile
VS-009 – Drug Profile
VX-121 + deutivacaftor + tezacaftor – Drug Profile
VX-551 – Drug Profile
VXc-0522 – Drug Profile
VXc-522 – Drug Profile
XF-70 – Drug Profile
YPT-01 – Drug Profile
zelpultide alfa – Drug Profile
Cystic Fibrosis – Dormant Projects
Cystic Fibrosis – Discontinued Products
Cystic Fibrosis – Product Development Milestones
Featured News & Press Releases
Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound
Jul 07, 2022: Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for public reimbursement of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children With cystic fibrosis ages 6 and older
Jun 11, 2022: Vertex to present data demonstrating significant benefits of long-term and early treatment With CFTR modulators at the European Cystic Fibrosis Conference
May 18, 2022: Recode therapeutics presents new preclinical data from mRNA-based program for cystic fibrosis at the ATS 2022 International Conference
Apr 21, 2022: Health Canada approves Vertex’s Trikafta for cystic fibrosis in children
Apr 18, 2022: ContraFect announces multiple presentations of new data demonstrating the potential of its Direct Lytic Agent CF-370 to address antimicrobial resistance at the 32nd Annual ECCMID Meeting
Apr 12, 2022: Entrinsic Bioscience steps closer to amino acid formulation as therapy for cystic fibrosis
Apr 11, 2022: Nabriva Therapeutics announces first patient enrolled in phase 1 trial of XENLETA (lefamulin) in adult patients with cystic fibrosis
Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine
Mar 29, 2022: Eloxx Pharmaceuticals announces therapeutic development Award from Cystic Fibrosis Foundation
Mar 26, 2022: Vertex announces reimbursement agreement in Australia for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients With cystic fibrosis ages 12 years and older with at least one F508del mutation in the CFTR gene
Mar 25, 2022: Health Canada Grants Marketing Authorization for KALYDECO (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H Mutation in the CFTR Gene
Jan 12, 2022: EC approves Vertex’s combination therapy for cystic fibrosis in children
Jan 05, 2022: SpliSense announces FDA and EMA grant Orphan Drug Designation to SPL84-23-1 for the treatment of cystic fibrosis
Jan 05, 2022: Peptilogics receives award from the Cystic Fibrosis Foundation to investigate PLG0301 as potential dual-acting treatments for lung infections associated with cystic fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Cystic Fibrosis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
Table 9: Number of Products under Development by Universities/Institutes, 2022
Table 10: Products under Development by Companies, 2022
Table 11: Products under Development by Companies, 2022 (Contd..1)
Table 12: Products under Development by Companies, 2022 (Contd..2)
Table 13: Products under Development by Companies, 2022 (Contd..3)
Table 14: Products under Development by Companies, 2022 (Contd..4)
Table 15: Products under Development by Companies, 2022 (Contd..5)
Table 16: Products under Development by Companies, 2022 (Contd..6)
Table 17: Products under Development by Companies, 2022 (Contd..7)
Table 18: Products under Development by Companies, 2022 (Contd..8)
Table 19: Products under Development by Companies, 2022 (Contd..9)
Table 20: Products under Development by Universities/Institutes, 2022
Table 21: Number of Products by Stage and Target, 2022
Table 22: Number of Products by Stage and Target, 2022 (Contd..1)
Table 23: Number of Products by Stage and Mechanism of Action, 2022
Table 24: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 25: Number of Products by Stage and Route of Administration, 2022
Table 26: Number of Products by Stage and Molecule Type, 2022
Table 27: Cystic Fibrosis – Pipeline by 4D Molecular Therapeutics Inc, 2022
Table 28: Cystic Fibrosis – Pipeline by AbbVie Inc, 2022
Table 29: Cystic Fibrosis – Pipeline by Abeona Therapeutics Inc, 2022
Table 30: Cystic Fibrosis – Pipeline by Aceragen Inc, 2022
Table 31: Cystic Fibrosis – Pipeline by Aeon Respire Inc, 2022
Table 32: Cystic Fibrosis – Pipeline by Agile Sciences Inc, 2022
Table 33: Cystic Fibrosis – Pipeline by AiCuris Anti-infective Cures AG, 2022
Table 34: Cystic Fibrosis – Pipeline by Airbase Breathing Co LLC, 2022
Table 35: Cystic Fibrosis – Pipeline by Airway Therapeutics Inc, 2022
Table 36: Cystic Fibrosis – Pipeline by AlgiPharma AS, 2022
Table 37: Cystic Fibrosis – Pipeline by Antabio SAS, 2022
Table 38: Cystic Fibrosis – Pipeline by Arch Biopartners Inc, 2022
Table 39: Cystic Fibrosis – Pipeline by Arcturus Therapeutics Holdings Inc, 2022
Table 40: Cystic Fibrosis – Pipeline by Armata Pharmaceuticals Inc, 2022
Table 41: Cystic Fibrosis – Pipeline by Arrevus Inc, 2022
Table 42: Cystic Fibrosis – Pipeline by Arrowhead Pharmaceuticals Inc, 2022
Table 43: Cystic Fibrosis – Pipeline by Astria Therapeutics Inc, 2022
Table 44: Cystic Fibrosis – Pipeline by Atlantic Healthcare Plc, 2022
Table 45: Cystic Fibrosis – Pipeline by Avidin Biotechnology Ltd, 2022
Table 46: Cystic Fibrosis – Pipeline by Biofilm Pharma, 2022
Table 47: Cystic Fibrosis – Pipeline by Biolytx Pharmaceuticals Corp, 2022
Table 48: Cystic Fibrosis – Pipeline by BiomX Inc, 2022
Table 49: Cystic Fibrosis – Pipeline by Boehringer Ingelheim International GmbH, 2022
Table 50: Cystic Fibrosis – Pipeline by Boston Pharmaceuticals Inc, 2022
Table 51: Cystic Fibrosis – Pipeline by Branca Bunus Ltd, 2022
Table 52: Cystic Fibrosis – Pipeline by Breathe Easy Therapeutics Ltd, 2022
Table 53: Cystic Fibrosis – Pipeline by BridgeBio Pharma Inc, 2022
Table 54: Cystic Fibrosis – Pipeline by Calista Therapeutics Inc, 2022
Table 55: Cystic Fibrosis – Pipeline by Calithera Biosciences Inc, 2022
Table 56: Cystic Fibrosis – Pipeline by Carbon Biosciences Inc, 2022
Table 57: Cystic Fibrosis – Pipeline by Chiesi Farmaceutici SpA, 2022
Table 58: Cystic Fibrosis – Pipeline by Cilian AG, 2022
Table 59: Cystic Fibrosis – Pipeline by Clarametyx Biosciences Inc, 2022
Table 60: Cystic Fibrosis – Pipeline by ContraFect Corp, 2022
Table 61: Cystic Fibrosis – Pipeline by Copernicus Therapeutics Inc, 2022
Table 62: Cystic Fibrosis – Pipeline by CRISPR Therapeutics AG, 2022
Table 63: Cystic Fibrosis – Pipeline by CSA Biotechnologies LLC, 2022
Table 64: Cystic Fibrosis – Pipeline by Cyclacel Pharmaceuticals Inc, 2022
Table 65: Cystic Fibrosis – Pipeline by Cyclenium Pharma Inc, 2022
Table 66: Cystic Fibrosis – Pipeline by Destiny Pharma Plc, 2022
Table 67: Cystic Fibrosis – Pipeline by DiscoveryBiomed Inc, 2022
Table 68: Cystic Fibrosis – Pipeline by Editas Medicine Inc, 2022
Table 69: Cystic Fibrosis – Pipeline by Eloxx Pharmaceuticals Inc, 2022
Table 70: Cystic Fibrosis – Pipeline by EmphyCorp Inc, 2022
Table 71: Cystic Fibrosis – Pipeline by enGene Inc, 2022
Table 72: Cystic Fibrosis – Pipeline by Enterprise Therapeutics Ltd, 2022
Table 73: Cystic Fibrosis – Pipeline by Entrinsic Bioscience Inc, 2022
Table 74: Cystic Fibrosis – Pipeline by Evaxion Biotech ApS, 2022
Table 75: Cystic Fibrosis – Pipeline by Evotec SE, 2022
Table 76: Cystic Fibrosis – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 77: Cystic Fibrosis – Pipeline by Feldan Therapeutics Inc, 2022
Table 78: Cystic Fibrosis – Pipeline by Felix Biotechnology Inc, 2022
Table 79: Cystic Fibrosis – Pipeline by Helperby Therapeutics Group Ltd, 2022
Table 80: Cystic Fibrosis – Pipeline by Hunterian Medicine LLC, 2022
Table 81: Cystic Fibrosis – Pipeline by Icagen Inc, 2022
Table 82: Cystic Fibrosis – Pipeline by Insmed Inc, 2022
Table 83: Cystic Fibrosis – Pipeline by Invion Ltd, 2022
Table 84: Cystic Fibrosis – Pipeline by Kamada Pharmaceuticals, 2022
Table 85: Cystic Fibrosis – Pipeline by Kither Biotech Srl, 2022
Table 86: Cystic Fibrosis – Pipeline by Krystal Biotech Inc, 2022
Table 87: Cystic Fibrosis – Pipeline by Lakewood-Amedex Inc, 2022
Table 88: Cystic Fibrosis – Pipeline by Lamellar Biomedical Ltd, 2022
Table 89: Cystic Fibrosis – Pipeline by Laurent Pharmaceuticals Inc, 2022
Table 90: Cystic Fibrosis – Pipeline by Loxegen Pty Ltd, 2022
Table 91: Cystic Fibrosis – Pipeline by MannKind Corp, 2022
Table 92: Cystic Fibrosis – Pipeline by Mariposa Health Ltd, 2022
Table 93: Cystic Fibrosis – Pipeline by Microbion Corp, 2022
Table 94: Cystic Fibrosis – Pipeline by Mucokinetica Ltd, 2022
Table 95: Cystic Fibrosis – Pipeline by Nabriva Therapeutics Plc, 2022
Table 96: Cystic Fibrosis – Pipeline by Nanogenics Ltd, 2022
Table 97: Cystic Fibrosis – Pipeline by Neupharma Srl, 2022
Table 98: Cystic Fibrosis – Pipeline by New Amsterdam Sciences Inc, 2022
Table 99: Cystic Fibrosis – Pipeline by Novabiotics Ltd, 2022
Table 100: Cystic Fibrosis – Pipeline by Omnispirant Ltd, 2022
Table 101: Cystic Fibrosis – Pipeline by Orphomed Inc, 2022
Table 102: Cystic Fibrosis – Pipeline by OrPro Therapeutics Inc, 2022
Table 103: Cystic Fibrosis – Pipeline by Oryn Therapeutics, 2022
Table 104: Cystic Fibrosis – Pipeline by Parion Sciences Inc, 2022
Table 105: Cystic Fibrosis – Pipeline by Peptilogics Inc, 2022
Table 106: Cystic Fibrosis – Pipeline by Peter Biotherapeutics Inc, 2022
Table 107: Cystic Fibrosis – Pipeline by Pharmaero ApS, 2022
Table 108: Cystic Fibrosis – Pipeline by PhaseBio Pharmaceuticals Inc, 2022
Table 109: Cystic Fibrosis – Pipeline by Progenra Inc, 2022
Table 110: Cystic Fibrosis – Pipeline by Prolong Pharmaceuticals LLC, 2022
Table 111: Cystic Fibrosis – Pipeline by PureIMS BV, 2022
Table 112: Cystic Fibrosis – Pipeline by Pylum Biosciences Inc, 2022
Table 113: Cystic Fibrosis – Pipeline by RAGE Biotech Pty Ltd, 2022
Table 114: Cystic Fibrosis – Pipeline by Rare Partners Srl, 2022
Table 115: Cystic Fibrosis – Pipeline by Reata Pharmaceuticals Inc, 2022
Table 116: Cystic Fibrosis – Pipeline by Recode Therapeutics Inc, 2022
Table 117: Cystic Fibrosis – Pipeline by Renovion Inc, 2022
Table 118: Cystic Fibrosis – Pipeline by Respirion Pharmaceuticals Pty Ltd, 2022
Table 119: Cystic Fibrosis – Pipeline by Riptide Bioscience Inc, 2022
Table 120: Cystic Fibrosis – Pipeline by RS BioTherapeutics Inc, 2022
Table 121: Cystic Fibrosis – Pipeline by Saliogen Therapeutics Inc, 2022
Table 122: Cystic Fibrosis – Pipeline by San Rocco Therapeutics LLC, 2022
Table 123: Cystic Fibrosis – Pipeline by Sanofi, 2022
Table 124: Cystic Fibrosis – Pipeline by Santhera Pharmaceuticals Holding AG, 2022
Table 125: Cystic Fibrosis – Pipeline by Sarcomed AB, 2022
Table 126: Cystic Fibrosis – Pipeline by SciBac Inc, 2022
Table 127: Cystic Fibrosis – Pipeline by SciClone Pharmaceuticals Holdings Ltd, 2022
Table 128: Cystic Fibrosis – Pipeline by Shape Therapeutics Inc, 2022
Table 129: Cystic Fibrosis – Pipeline by Silurian Pharmaceuticals Inc, 2022
Table 130: Cystic Fibrosis – Pipeline by Sionna Therapeutics Inc, 2022
Table 131: Cystic Fibrosis – Pipeline by SOLA Biosciences LLC, 2022
Table 132: Cystic Fibrosis – Pipeline by SolAeroMed Inc, 2022
Table 133: Cystic Fibrosis – Pipeline by Specific Biologics Inc, 2022
Table 134: Cystic Fibrosis – Pipeline by Spexis AG, 2022
Table 135: Cystic Fibrosis – Pipeline by Spirovant Sciences Inc, 2022
Table 136: Cystic Fibrosis – Pipeline by SpliSense Ltd, 2022
Table 137: Cystic Fibrosis – Pipeline by Synedgen Inc, 2022
Table 138: Cystic Fibrosis – Pipeline by Synovo GmbH, 2022
Table 139: Cystic Fibrosis – Pipeline by Synspira Therapeutics Inc, 2022
Table 140: Cystic Fibrosis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Table 141: Cystic Fibrosis – Pipeline by Tavanta Therapeutics Inc, 2022
Table 142: Cystic Fibrosis – Pipeline by TGV-Inhalonix Inc, 2022
Table 143: Cystic Fibrosis – Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
Table 144: Cystic Fibrosis – Pipeline by Thirty Respiratory Ltd, 2022
Table 145: Cystic Fibrosis – Pipeline by Translate Bio Inc, 2022
Table 146: Cystic Fibrosis – Pipeline by Vast Therapeutics Inc, 2022
Table 147: Cystic Fibrosis – Pipeline by Vectura Group Plc, 2022
Table 148: Cystic Fibrosis – Pipeline by Vera Therapeutics Inc, 2022
Table 149: Cystic Fibrosis – Pipeline by Verona Pharma Plc, 2022
Table 150: Cystic Fibrosis – Pipeline by Vertex Pharmaceuticals Inc, 2022
Table 151: Cystic Fibrosis – Pipeline by VGSK Technologies Inc, 2022
Table 152: Cystic Fibrosis – Pipeline by Vironika LLC, 2022
Table 153: Cystic Fibrosis – Pipeline by Yumanity Therapeutics Inc, 2022
Table 154: Cystic Fibrosis – Pipeline by Zambon Co SpA, 2022
Table 155: Cystic Fibrosis – Pipeline by Zata Pharmaceuticals Inc, 2022
Table 156: Cystic Fibrosis – Dormant Projects, 2022
Table 157: Cystic Fibrosis – Dormant Projects, 2022 (Contd..1)
Table 158: Cystic Fibrosis – Dormant Projects, 2022 (Contd..2)
Table 159: Cystic Fibrosis – Dormant Projects, 2022 (Contd..3)
Table 160: Cystic Fibrosis – Dormant Projects, 2022 (Contd..4)
Table 161: Cystic Fibrosis – Dormant Projects, 2022 (Contd..5)
Table 162: Cystic Fibrosis – Dormant Projects, 2022 (Contd..6)
Table 163: Cystic Fibrosis – Dormant Projects, 2022 (Contd..7)
Table 164: Cystic Fibrosis – Dormant Projects, 2022 (Contd..8)
Table 165: Cystic Fibrosis – Dormant Projects, 2022 (Contd..9)
Table 166: Cystic Fibrosis – Dormant Projects, 2022 (Contd..10)
Table 167: Cystic Fibrosis – Discontinued Products, 2022
Table 168: Cystic Fibrosis – Discontinued Products, 2022 (Contd..1)
List of Figures
Figure 1: Number of Products under Development for Cystic Fibrosis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings